{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-110303","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.341734+00:00","generated_at":"2026-05-29T01:53:13.003105+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Oruka Therapeutics enters exclusive IL-23 license with Paragon; up to $22M milestones","bullets":["Oruka grants exclusive worldwide license for anti-IL-23 antibodies (ORKA-001) from Paragon, excluding inflammatory bowel disease.","Milestone payments up to $22M including $1.5M for development candidate nomination and $2.5M for first Phase 1 dosing.","Low single-digit royalty on antibody products; royalty term ends 12 years after first sale or last-to-expire patent.","Paragon will not conduct new anti-IL-23 monospecific antibody campaigns in Field for at least 5 years.","Company may terminate on 60 days notice; agreement also subject to material breach and insolvency provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-110303","json":"https://secwatch.observer/filing/0001213900-24-110303.json","markdown":"https://secwatch.observer/filing/0001213900-24-110303.md","text":"https://secwatch.observer/filing/0001213900-24-110303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000121390024110303/0001213900-24-110303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000121390024110303/ea0225145-8k_oruka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:53:13.003105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}